These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35595169)

  • 21. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity.
    Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM
    J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites.
    Tong M; Pelton JG; Gill ML; Zhang W; Picart F; Seeliger MA
    Nat Commun; 2017 Dec; 8(1):2160. PubMed ID: 29255153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Protein Allosteric Signalling Pathways and Functional Residues Through Paths of Optimised Propensity.
    Wu N; Yaliraki SN; Barahona M
    J Mol Biol; 2022 Sep; 434(17):167749. PubMed ID: 35841931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allosteric lariat peptide inhibitors of Abl kinase.
    Bharathikumar VM; Barreto K; Decoteau JF; Geyer CR
    Chembiochem; 2013 Nov; 14(16):2119-25. PubMed ID: 24030821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AlphaFold-SFA: Accelerated sampling of cryptic pocket opening, protein-ligand binding and allostery by AlphaFold, slow feature analysis and metadynamics.
    Vats S; Bobrovs R; Söderhjelm P; Bhakat S
    PLoS One; 2024; 19(8):e0307226. PubMed ID: 39190764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does a drug molecule find its target binding site?
    Shan Y; Kim ET; Eastwood MP; Dror RO; Seeliger MA; Shaw DE
    J Am Chem Soc; 2011 Jun; 133(24):9181-3. PubMed ID: 21545110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
    Fang L; Vilas-Boas J; Chakraborty S; Potter ZE; Register AC; Seeliger MA; Maly DJ
    ACS Chem Biol; 2020 Jul; 15(7):2005-2016. PubMed ID: 32479050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
    Hill ZB; Perera BG; Maly DJ
    Mol Biosyst; 2011 Feb; 7(2):447-56. PubMed ID: 21060940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric Regulation of Protein Kinases Downstream of PI3-Kinase Signalling.
    Leroux AE; Gross LZF; Sacerdoti M; Biondi RM
    Adv Exp Med Biol; 2019; 1163():279-311. PubMed ID: 31707708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case.
    Spitaleri A; Zia SR; Di Micco P; Al-Lazikani B; Soler MA; Rocchia W
    J Phys Chem Lett; 2021 Jan; 12(1):49-58. PubMed ID: 33300337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based virtual screening of Src kinase inhibitors.
    Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exquisitely specific bisubstrate inhibitors of c-Src kinase.
    Brandvold KR; Santos SM; Breen ME; Lachacz EJ; Steffey ME; Soellner MB
    ACS Chem Biol; 2015 Jun; 10(6):1387-91. PubMed ID: 25793938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
    Yilmaz OG; Olmez EO; Ulgen KO
    Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70.
    O'Connor S; Le Bihan YV; Westwood IM; Liu M; Mak OW; Zazeri G; Povinelli APR; Jones AM; van Montfort R; Reynisson J; Collins I
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single Binding Pockets Versus Allosteric Binding.
    Song K; Zhang J
    Methods Mol Biol; 2018; 1825():295-326. PubMed ID: 30334210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis for selective inhibition of Src family kinases by PP1.
    Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
    Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allosteric modulation of a human protein kinase with monobodies.
    Zorba A; Nguyen V; Koide A; Hoemberger M; Zheng Y; Kutter S; Kim C; Koide S; Kern D
    Proc Natl Acad Sci U S A; 2019 Jul; 116(28):13937-13942. PubMed ID: 31239342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.